Literature DB >> 9145977

Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma.

M Bazinet1, W Zheng, L R Bégin, A G Aprikian, P I Karakiewicz, M M Elhilali.   

Abstract

OBJECTIVE: Neoadjuvant androgen ablation (NAAA) causes significant cytoarchitectural changes in both benign and malignant prostatic epithelial cells that may contribute to underdetection of prostate cancer capsular involvement and positive surgical margins.
METHODS: The aim of this study is to determine the ability of cytokeratin immunohistochemistry to enhance the determination of pathologic stage of prostate cancer following NAAA.
RESULTS: Cytokeratin AE1/AE3 immunohistochemistry identified 6 (27.3%), 15 (68.2%), 5 (22.7%), and 5 (22.7%) cases of organ-confined disease, capsule penetration, positive surgical margin, and seminal vesicle involvement, respectively, as compared with 10 (45.5%), 10 (45.5%), 3 (13.6%), and 5 (22.7%) cases by hematoxylin-eosin (H&E) staining, respectively. Two cases without detectable tumor by H&E staining had demonstrable residual tumor by cytokeratin immunohistochemical staining.
CONCLUSIONS: Cytokeratin immunohistochemistry revealed more extensive intracapsular, capsular, and extracapsular tumor involvement and higher rate of positive surgical margin than did conventional H&E staining. Therefore, the beneficial pathologic effects of NAAA observed may, in part, be attributable to the artifact of observation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9145977     DOI: 10.1016/S0090-4295(97)00062-9

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

1.  [Therapy induced regressive changes of prostate cancer].

Authors:  B Helpap; J Köllermann
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

Review 2.  Pathological changes in prostate lesions after androgen manipulation.

Authors:  R Montironi; C C Schulman
Journal:  J Clin Pathol       Date:  1998-01       Impact factor: 3.411

3.  Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial.

Authors:  David S Yee; William T Lowrance; James A Eastham; Alexandra C Maschino; Angel M Cronin; Farhang Rabbani
Journal:  BJU Int       Date:  2009-07-08       Impact factor: 5.588

Review 4.  Prostate cancer, Incidence, management and outcomes.

Authors:  E J Small
Journal:  Drugs Aging       Date:  1998-07       Impact factor: 3.923

5.  Prostate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal Therapy.

Authors:  Sung Han Kim; Weon Seo Park; Sun Ho Kim; Boram Park; Jungnam Joo; Geon Kook Lee; Jae Young Joung; Ho Kyung Seo; Jinsoo Chung; Kang Hyun Lee
Journal:  PLoS One       Date:  2016-03-16       Impact factor: 3.240

6.  Radical prostatectomy in locally advanced cancer - an indispensable onset of multimodal therapy?

Authors:  Wojciech Malewski; Jakub Dobruch
Journal:  Cent European J Urol       Date:  2017-03-14

7.  The role of chemotherapy and new targeted agents in the management of primary prostate cancer.

Authors:  Sanjeev Srinivas Kumar; Simon Pacey
Journal:  J Clin Urol       Date:  2016-12-01

8.  Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy.

Authors:  Roberta Mazzucchelli; Francesca Barbisan; Adriano Tagliabracci; Antonio Lopez-Beltran; Liang Cheng; Marina Scarpelli; Rodolfo Montironi
Journal:  Virchows Arch       Date:  2007-02-07       Impact factor: 4.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.